Clinical and Translational Medicine (Sep 2020)

Response of patients with chest tightness variant asthma with routine asthma treatment regimen: A 1‐year multicenter, prospective, real‐world study

  • Fugui Yan,
  • Wen Li,
  • Wei‐jie Guan,
  • Min Chen,
  • Chen Qiu,
  • Wei Tang,
  • Xiansheng Liu,
  • Xudong Xiang,
  • Jing Li,
  • Meiling Jin,
  • Yuanrong Dai,
  • Ping Chen,
  • Xiaohong Wu,
  • Zhongmin Qiu,
  • Liang Dong,
  • Limin Zhao,
  • Xiaoping Lin,
  • Changgui Wu,
  • Bin Wu,
  • Yalian Yuan,
  • Fei Shi,
  • Ting Zhang,
  • Jun Zhou,
  • Min Xie,
  • Xiaoyu Fang,
  • Hongliang Zhang,
  • Bing Xiao,
  • Mo Xian,
  • Jian Wang,
  • Zhangwei Qiu,
  • Jie Lin,
  • Bingbing Ji,
  • Yong Zhou,
  • Yu Li,
  • Chunhong Liu,
  • Yiping Chen,
  • Yiming Zeng,
  • Lingli Liu,
  • Wen Hua,
  • Huaqiong Huang,
  • Jiesen Zhou,
  • Yue Hu,
  • Luanqing Che,
  • Songmin Ying,
  • Zhihua Chen,
  • Nanshan Zhong,
  • Huahao Shen

DOI
https://doi.org/10.1002/ctm2.178
Journal volume & issue
Vol. 10, no. 5
pp. n/a – n/a

Abstract

Read online

Abstract Background Asthmatic patients with chest tightness as their only presenting symptom (chest tightness variant asthma [CTVA]) have clinical characteristics of eosinophilic airway inflammation similar to those of classic asthma (CA); however, whether CTVA has similar response to antiasthma treatment as compared with CA remains unclear. Objective The response of 76 CTVA patients to standard asthma treatments with inhaled corticosteroids with long‐acting beta‐agonists was explored in a 52‐week multicenter, prospective, real‐world study. Results After 52 weeks of treatment with therapy regimens used for CA, the mean 5‐point Asthma Control Questionnaire (ACQ‐5) score decreased markedly from 1.38(first administration) to 0.71 (52 weeks, mean decrease: 0.674, 95%CI: 0.447‐0.900, P<.001).The mean asthma quality‐of‐life questionnaire (AQLQ) score increased from 5.77 (first administration) to 6.20 (52 weeks, mean increase: 0.441, 95% CI 0.258‐0.625, P<.001). Furthermore, at week 52, FVC, FEV1%, the diurnal variation in PEFand the PD20‐FEV1 were significantly improved. Subgroup analysis revealed that the patients at first administration in the responsive group had higher ACQ‐5 scores than those in the nonresponsive group (P < .05). Conclusion In conclusion, patients with CTVA had a good therapeutic response to the guideline‐recommended routine treatment (containing inhaled corticosteroids). The association between the treatment response and the severity of CTVA suggested that CTVA patients with higher ACQ‐5 scores had better therapeutic effects.

Keywords